thumbnail
VC/PE'Is the worst behind us?' Financial expert talks biotech funding'Is the worst behind us?' Financial expert talks biotech funding
Biotech venture funding has recovered during the first two quarters of 2024 but IPO activity remains sluggish, according to Brian Scanlan, partner at Edgewater Capital.
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.